



Institutional Biohazardous Committee Use Form

SECTION A: Principal Investigator and personnel information (please type or print)

P.I. Name

Title:

For purposes of this registration, biohazardous materials are defined as any organism known to or suspected of causing infection in humans, and a toxin is a proteinaceous poison which is highly toxic to humans. Experiments using biohazardous materials and toxins should follow the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) Guidelines (4th Edition, 1999).

Experiments using recombinant DNA technology should follow the NIH Guidelines for Research Involving Recombinant DNA (rDNA) Molecules, (April 2002)

The Principal Investigator (PI) is responsible for completing the appropriate parts of this registration document. The Lamar University Institutional Biosafety Committee (IBC), in conjunction with the Environmental Health, Safety and Risk Management Department (EHS & RM), maintains a registry of all laboratories and personnel working with human pathogens, and/or toxins, human blood, body fluids, and tissues, and recombinant DNA technology.

The PI is also responsible for notifying the Research Compliance Specialist as well as EHS when work with any potentially infectious material is terminated or when other significant changes occur, such as changes in personnel or relocation of the laboratory.

This registration document is to be forwarded to the Research Compliance Specialist prior to the initiation of work. Everyone listed should be informed of the potential hazards associated with this work, the appropriate safety practices to be used, the availability of medical programs, and applicable training requirements.

EHS conducts an annual inspection of registered laboratories to review practices and procedures. The survey is

B.4. Types of biological agents and toxins, their quantity, duration of experiment, and/or the rDNA technology applied

B.5. Significance of the project

B.6. Please include any additional information that may assist in the review of this protocol (e.g. description of experimental design, procedures, etc)

SECTION C: Use of recombinant DNA technology ..Not Applicable

Prokaryotic Hosts/ Eukaryotic Cells List Strains	Vector	DNA Insert	Relevant section of NIH Guidelines	Physical Containments

If viral vector is to be used will infectious virus be generated? ..No ...Yes

Will studies include attempts to obtain expressible foreign gene, other than those used for selection purposes?
 ..No

SECTION F: Handling of Human Products (requires BSL practices or above)

Are Human samples used in this project? No Yes Date IRB Approval (if Applicable) _____

Type of human samples manipulated

Cell lines Blood Tissues Urine Spinal Fluid Serum Feces Semen

Other _____ Specify _____

Type of manipulations:

Centrifugation Bleeding/Mixing Dissection Sonication Pipetting

Other _____

SECTION G: Safety Security, and Training Plan- U